(firstQuint)Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.

w/Partial Epilepsy Not Well Controlled by Current Antiepileptic.

 This is an 18-week, double-blind, randomized, historical control, multicenter study with gradual conversion to monotherapy in subjects with partial onset seizures who are not well controlled by current AEDs.

 The 18 week double-blind treatment period consists of a 2-week titration period, 6-week taper or conversion period, and a 10-week monotherapy period.

 This study was previously posted by Sepracor Inc.

 In October 2009, Sepracor Inc.

 was acquired by Dainippon Sumitomo Pharma.

, and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

.

 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.

w/Partial Epilepsy Not Well Controlled by Current Antiepileptic@highlight

This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.

